Yuheng Pharmaceutical: Announcement on Litigation Progress and Termination of Execution
Harbin Yuheng Pharmaceutical Co., Ltd.
Securities code: 002437 Securities abbreviation: Yuheng Pharmaceutical Announcement number: 2026-004
Harbin Yuheng Pharmaceutical Co., Ltd.
Announcement on Litigation Progress and Termination of Execution
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
Special tips:
The litigation stage of the case: termination of execution;
The party status of Harbin Yuheng Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company"): plaintiff in the first instance, appellee in the second instance, and person applying for execution;
Amount involved: 132 million yuan;
The impact of the case on the company's profits and losses: The 132 million yuan received by the company will be included in the company's non-recurring profits and losses in 2025. This part of the income is a one-time income and is not sustainable. The specific financial impact is subject to the annual audit report.
1. Basic information about this lawsuit
Because Qingdao Pu Sheng Puli Enterprise Management Center (Limited Partnership) (hereinafter referred to as "Pu Sheng Puli") failed to pay the company the equity transfer fee of 117.6 million yuan for the purchase of 42.12% equity of Guangzhou Yuheng Biotechnology Co., Ltd. (hereinafter referred to as "Yuheng Bio") within the agreed time, the company entrusted Beijing Haotian Law Firm to submit a civil complaint and other filing materials to the court on April 9, 2024. On April 18, 2024, the company learned that the court had accepted the case. For details, please refer to the "Announcement Regarding the Company's Litigation" disclosed by the company on April 20, 2024 in the Securities Times, China Securities Journal and the Juchao Information Network http://www.cninfo.com.cn (hereinafter referred to as the "Designated Media").
On December 27, 2024, the company received the "Civil Judgment" ((2024) Jing 03 Minchu No. 1863) issued by the Beijing No. 3 Intermediate People's Court, and the Beijing No. 3 Intermediate People's Court made a first-instance judgment on the case. For details, please refer to the "Announcement on the Progress of the Litigation" disclosed by the company in designated media on December 28, 2024.
Page 1
Harbin Yuheng Pharmaceutical Co., Ltd.
Subsequently, Pushengpri appealed to the Beijing Higher People's Court, and the Beijing Higher People's Court filed the case. For details, please refer to the "Announcement on the Progress of the Litigation" disclosed by the company in designated media on February 28, 2025.
On March 31, 2025, the company received the "Civil Judgment" ((2025) Jingminzhong No. 92) issued by the Beijing Higher People's Court. For details, please refer to the "Announcement on Litigation Progress and Receipt of the Second Instance Civil Judgment" disclosed by the company in designated media on April 1, 2025.
2. Progress of this litigation
On October 31, 2025, the company plans to resolve the debt dispute between the company and Pushengpri regarding the equity transfer payment of Yuheng Biotechnology Co., Ltd. by signing the "Agreement of Guangzhou Yuheng Biotechnology Co., Ltd." (hereinafter referred to as the "Agreement"). For details, please refer to the "Announcement on the Signing of the Agreement of Guangzhou Yuheng Biotechnology Co., Ltd." disclosed by the company in designated media on November 4, 2025.
On December 8, 2025, the company received a payment of 132 million yuan. For details, please refer to the "Progress Announcement on the Signing of the Agreement of Guangzhou Yuheng Biotechnology Co., Ltd." disclosed by the company in designated media on December 9, 2025.
After receiving the above-mentioned 132 million yuan, the company has applied to the Beijing No. 3 Intermediate People's Court to revoke the judicial execution proceedings against Pushengpri and its executive partners in accordance with the Agreement. As of now, the execution procedure of this case has been concluded.
3. The impact of this lawsuit on the company
The 132 million yuan received by the company will be included in the company's non-recurring profits and losses in 2025. This part of the income is a one-time income and is not sustainable. The specific financial impact is subject to the annual audit report.
4. Other litigation and arbitration matters
As of the disclosure date of this announcement, the company has no other major litigation or arbitration matters that should be disclosed but have not been disclosed.
5. Other tips
The company's designated information disclosure media are China Securities Journal, Securities Times and Juchao Information Network. Investors are advised to make prudent decisions and pay attention to investment risks.
6. Documents for reference
- "Case Closing Instructions" issued by Beijing Haotian Law Firm.
Announcement is hereby made.
Page 2
Harbin Yuheng Pharmaceutical Co., Ltd.
Board of Directors of Harbin Yuheng Pharmaceutical Co., Ltd.
January 15, 2026
Page 3